MRI assessment of hemodynamic effects of angiopoietin-2 overexpression in a brain tumor model

Neuro-Oncology

Volumn 11, Issue 5, 2009, Pages 488-502

  Valable, Samuel ^a   Eddi, Dauphou ^a   Constans, Jean Marc ^a,b   Guillamo, Jean Sébastien ^a,b   Bernaudin, Myriam ^a   Roussel, Simon ^a   Petit, Edwige ^a  

^a GIP CYCERON   (France)

^b CHU CÔTE DE NACRE   (France)

Author keywords

Angiogenesis; Angiopoietin 2; Cerebral blood volume; Glioma; MRI

Indexed keywords

ANGIOPOIETIN 2;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL PERMEABILITY; BLOOD VOLUME; BRAIN TUMOR; CANCER GROWTH; CANCER SURVIVAL; GENE OVEREXPRESSION; GLIOBLASTOMA; HEMODYNAMICS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; TUMOR GROWTH; TUMOR MODEL; TUMOR REGRESSION; VASCULAR TUMOR;

ANGIOPOIETIN-2; ANIMALS; BLOTTING, WESTERN; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; GLIOMA; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MALE; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, INBRED F344; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; UP-REGULATION;

EID: 70349622986     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-117     Document Type: Article

References (41)

1. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol. 1998;153:1459-1466. (Pubitemid 28509902)
2. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002;94:883-893. (Pubitemid 34778087)
3. Andreasson P, Carlsson R. Targeting angiogenesis with antibodies for the treatment of cancer. IDrugs. 2005;8:730-733. (Pubitemid 41269359)
4. Konner J, Dupont J. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer. 2004;4(suppl 2): S81-S85. (Pubitemid 39440148)
5. Ueda Y, Yamagishi T, Ikeya H, et al. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo. Anticancer Res. 2004;24:3009-3017. (Pubitemid 39407179)
6. Quarles CC, Schmainda KM. Assessment of the morphological and functional effects of the anti-angiogenic agent SU11657 on 9L gliosarcoma vasculature using dynamic susceptibility contrast MRI. Magn Reson Med. 2007;57:680-687.
7. de Bouard S, Herlin P, Christensen JG, et al. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro-Oncology. 2007;9:412-423.
8. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8:299-309. (Pubitemid 41443415)
9. Mizukami Y, Jo WS, Duerr EM, et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med. 2005;11:992-997. (Pubitemid 41294446)
10. Cao Y, Sonveaux P, Liu S, et al. Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angio-genesis and tumor growth. Cancer Res. 2007;67:3835-3844. (Pubitemid 46762171)
11. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441:437-443. (Pubitemid 44050138)
12. Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 1999;286:2511-2514. (Pubitemid 30026340)
13. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55-60. (Pubitemid 27450643)
14. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284:1994-1998. (Pubitemid 29309448)
15. Zagzag D, Amirnovin R, Greco MA, et al. Vascular apoptosis and involution in gliomas precede neovasculature: a novel concept for glioma growth and angiogenesis. Lab Invest. 2000;80:837-849. (Pubitemid 30421801)
16. Lee OH, Fueyo J, Xu J, et al. Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia. 2006;8:419-428. (Pubitemid 43830749)
17. Machein MR, Knedla A, Knoth R, Wagner S, Neuschl E, Plate KH. Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. Am J Pathol. 2004;165:1557-1570. (Pubitemid 39435155)
18. Jackson A, Kassner A, Annesley-Williams D, Reid H, Zhu XP, Li KL. Abnormalities in the recirculation phase of contrast agent bolus passage in cerebral gliomas: comparison with relative blood volume and tumor grade. AJNR Am J Neuroradiol. 2002;23:7-14. (Pubitemid 34098254)
19. Valable S, Lemasson B, Farion R, et al. Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal in vivo and ex vivo study. NMR Biomed. 2008.
20. Pacary E, Legros H, Valable S, et al. Synergistic effects of CoCl(2) and ROCK inhibition on mesenchymal stem cell differentiation into neuron-like cells. J Cell Sci. 2006;119:2667-2678. (Pubitemid 44184003)
21. Valable S, Barbier EL, Bernaudin M, et al. In vivo MRI tracking of exogenous monocytes/macrophages targeting brain tumors in a rat model of glioma. Neuroimage. 2007;37(suppl 1): S47-S58. (Pubitemid 47239434)
22. Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol. 2006;27:859-867.
23. Fan G, Zang P, Jing F, Wu Z, Guo Q. Usefulness of diffusion/ perfusion-weighted MRI in rat gliomas: correlation with histopathology. Acad Radiol. 2005;12:640-651. (Pubitemid 40603692)
24. Hayashida Y, Hirai T, Morishita S, et al. Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol. 2006;27:1419-1425. (Pubitemid 44260120)
25. Kang SH, Cho HT, Devi S, et al. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res. 2006;66:11991-11997. (Pubitemid 46094213)
26. Ljungkvist AS, Bussink J, Rijken PF, Raleigh JA, Denekamp J, Van Der Kogel AJ. Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys. 2000;48:1529-1538. (Pubitemid 30838386)
27. Koga K, Todaka T, Morioka M, et al. Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res. 2001;61:6248-6254. (Pubitemid 32762564)
28. Oshima Y, Oshima S, Nambu H, et al. Different effects of angiopoietin- 2 in different vascular beds: new vessels are most sensitive. FASEB J. 2005;19:963-965. (Pubitemid 40827718)
29. Barbier EL, Lamalle L, Decorps M. Methodology of brain perfusion imaging. J Magn Reson Imaging. 2001;13:496-520.
30. Wintermark M, Sesay M, Barbier E, et al. Comparative overview of brain perfusion imaging techniques. Stroke. 2005;36:e83-e99. (Pubitemid 41266549)
31. Maeda M, Itoh S, Kimura H, et al. Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. Radiology. 1993;189:233-238. (Pubitemid 23292954)
32. Schmainda KM, Rand SD, Joseph AM, et al. Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. AJNR Am J Neuroradiol. 2004;25:1524-1532.
33. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62.
34. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6:553-563. (Pubitemid 40017699)
35. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004;18:338-340.
36. Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG, Koh GY. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3/-kinase/Akt signal transduction pathway. Oncogene. 2000;19:4549-4552. (Pubitemid 30756901)
37. Gamble JR, Drew J, Trezise L, et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res. 2000;87:603-607. (Pubitemid 30745356)
38. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A. 2002;99:11205-11210.
39. Ohab JJ, Fleming S, Blesch A, Carmichael ST. A neurovascular niche for neurogenesis after stroke. J Neurosci. 2006;26:13007-13016.
40. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3:24-40. (Pubitemid 43108832)
41. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11: 83-95. (Pubitemid 46075199)